Vogenx, Inc.

Overview

Compare with another stock.

• TickerVOGX on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersRaleigh, United States²
• Incorporated inDE³
• Business address3901 Barrett Drive, Suite 300, Raleigh, Nc 27609³
• Filer category, Emerging growth company³
• Legal formCorporation²
• LEI5299004KM33YCDWS6I69²
• StatusActive²
• LEI statusIssued and current²
• Registered addressc/o BUSINESS FILINGS INCORPORATED, 108 WEST 13TH ST, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 5006766²

See how the biggest companies compare on our leaderboards

Corporate structure

Vogenx, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Vogenx, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief financial officerSteven R. Delmar Aug 11, 2026 to now⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorJames Green named Jan 7, 2026¹⁰

Timeline

1. Oct 9, 20268-K Executive or director change; Regulation FD disclosure¹¹
2. Sep 22, 20268-K Executive or director change; Regulation FD disclosure¹²
3. Aug 19, 20268-K Other events¹³
4. Aug 13, 20268-K Bylaws or fiscal year changed¹⁴
5. Feb 5, 2021Founded Vogenx, Inc. is founded²

Filings

34 filings to the SEC since October 2021: 1 quarterly reports, 4 major events, 16 insider forms, 1 large holders, 1 private raises, 11 other. The latest 20:

1. Oct 9, 20268-K EDGAR
2. Oct 6, 20264 EDGAR
3. Oct 6, 20264 EDGAR
4. Oct 6, 20264 EDGAR
5. Oct 6, 20264 EDGAR
6. Oct 6, 20264 EDGAR
7. Oct 6, 20264 EDGAR
8. Sep 28, 20263 EDGAR
9. Sep 22, 20268-K EDGAR
10. Sep 17, 202610-Q EDGAR
11. Sep 8, 2026SCHEDULE 13G EDGAR
12. Aug 19, 20268-K EDGAR
13. Aug 13, 20264 EDGAR
14. Aug 13, 20264 EDGAR
15. Aug 13, 20268-K EDGAR
16. Aug 13, 2026S-8 EDGAR
17. Aug 12, 2026424B4 EDGAR
18. Aug 11, 2026EFFECT EDGAR
19. Aug 11, 2026CERT EDGAR
20. Aug 11, 20263 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Janus Henderson Group Ltd.SCHEDULE 13G, 1 filing Sep 8, 2026¹⁵

Money raised

Private offerings the company reported to the SEC on Form D.

1. Dec 10, 2025Raised $750,000 in a private offering of debt Form D: $5 million offered in all Form D

SEC filer profile

How Vogenx, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARVogenx, Inc.¹
• CIK0001903784
• Employer ID (EIN)86-3697324¹
• LEI5299004KM33YCDWS6I69¹
• Filer status<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address3901 Barrett Drive, Suite 300, Raleigh, NC 27609¹
• Mailing addressPo Box 19469, Raleigh, NC 27619¹
• Phone9196595677¹
• Shares outstanding14,855,087 as of Sep 17, 2026¹⁶
• On EDGAR sinceJan 7, 2026¹
• Filings34 in all: 3 (8), 4 (8), 8-K (4), DRS/A (2), S-1/A (2), 10-Q (1), 424B4 (1), 8-A12B (1)¹
  All 15 form types

  CERT (1), D (1), DRS (1), EFFECT (1), S-1 (1), S-8 (1), SCHEDULE 13G (1)

• Latest filingsQuarterly report (10-Q) Sep 17, 2026
  Latest 8-K (8-K) Oct 9, 2026